MOA Life Plus모아라이프플러스
142760 · KOSDAQ · ₩142760 · 모아라이프플러스
- Market cap
- ₩5.4B
- Enterprise value
- ₩4.8B
- P/E
- —
- P/B
- 0.2×
- Dividend yield
- 0.0%
- ROE
- −56.5%
- Net margin
- −130.7%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−93.2% from the high
₩257Today: ₩257 – ₩384₩3,788
Returns
- 1W−50.2%
- 1M−45.4%
- 3M−65.4%
- 6M−85.2%
- YTD−92.8%
- 1Y−92.6%
- Volume today
- 4,400,335
- 4.1× the 20-day average
- Traded today
- ₩1.2B
- Listed shares
- 21,083,490
- EPS (12 months)
- −₩648
- Earnings yield −252.3%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Why is it moving?
−29.8% on Oct 28, 2026. Trading value 2.0× its normal.
MOA Life Plus has filed several amended documents with regulators in late October 2026. The filings cover a change of largest shareholder, a rights offering to raise capital, a small-scale share offering, and a notice for a shareholders' meeting.
AI summary of the news and filings linked. It can be wrong; check them.
- • Filing: Amended: Change of largest shareholder
- • Filing: [Amended] Small-Scale Public Offering Disclosure Documents (Equity Securities)
- • Filing: [Amended] Reference Document for Proxy Solicitation of Voting Rights
- • Foreign investors bought a net ₩87M that day
- • Buzz 53 on JONBUR: heavy trading
Possible reasons, not certainties. Not financial advice.
Signals
Normal- BuzzNormalBuzz 53: heavy trading.
- MomentumWeak-45% over the last month; the price is below its 20-day average.
- News impactLow13 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
MOA Life Plus stock overview
MOA Life Plus (모아라이프플러스, KRX: 142760) is listed on KOSDAQ, in the Biotech & Pharma sector. The company develops biopharmaceutical drug candidates using its proprietary HumaMAX and MucoMAX platform technologies, with pipelines ranging from basic research to clinical studies. Its shares closed at ₩257 on Oct 28, 2026, down 29.78% on the day, giving it a market value of ₩5.4B.
Key facts
- Market cap
- ₩5.4B
- Sector
- Biotech & Pharma
- Latest price change
- −29.78%
- As of
- Oct 28, 2026
- Main business
- The company develops biopharmaceutical drug candidates using its proprietary HumaMAX and MucoMAX platform technologies, with pipelines ranging from basic research to clinical studies.
Quick answers about MOA Life Plus
- What does MOA Life Plus do?
- The company develops biopharmaceutical drug candidates using its proprietary HumaMAX and MucoMAX platform technologies, with pipelines ranging from basic research to clinical studies. It also runs a consumer business making and selling health functional foods and functional cosmetics based on polygamma-glutamic acid, including supply of cosmetic ingredients to European companies and exports of skincare brands to Southeast Asia and other overseas markets. In addition, its pharmaceutical division distributes prescription and general medicines and medical supplies through specialized distributors.
- What is the market cap of MOA Life Plus?
- The market capitalisation of MOA Life Plus was ₩5.4B at the close on Oct 28, 2026.
- Who are the largest shareholders of MOA Life Plus?
- According to the latest official filings, the largest reported holders are Moa Data (17.32%, as of Oct 15, 2026); Ricoh Asset Management (4.15%, as of Jan 14, 2026); Yun Sang-ho (0.71%, as of Sep 2, 2026).
- When is the next earnings report from MOA Life Plus?
- Korean companies rarely announce results dates in advance. Based on when MOA Life Plus filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Company profile
The company develops biopharmaceutical drug candidates using its proprietary HumaMAX and MucoMAX platform technologies, with pipelines ranging from basic research to clinical studies. It also runs a consumer business making and selling health functional foods and functional cosmetics based on polygamma-glutamic acid, including supply of cosmetic ingredients to European companies and exports of skincare brands to Southeast Asia and other overseas markets. In addition, its pharmaceutical division distributes prescription and general medicines and medical supplies through specialized distributors.
Written by AI from the company's latest annual report.
- Korean name
- 모아라이프플러스
- Sector
- Biotech & Pharma
- Themes
- —
- CEO
- 한상진
- Founded
- Dec 1999
- Listed
- Jul 2016
- Listed shares
- 21,083,490
- Fiscal year ends
- Month 12
- Website
- www.bioleaders.co.kr
Similar companies
- Samsung Biologics207940 · ₩64T₩1,372,000−0.15%
- Celltrion068270 · ₩44T₩189,800+0.64%
- Alteogen196170 · ₩16T₩223,000+2.06%
- SK biopharmaceuticals326030 · ₩5.9T₩75,200+0.40%
- Yuhan000100 · ₩5.7T₩77,300−3.38%
- HLB028300 · ₩5.4T₩40,650+1.88%
- Hanmi Pharm128940 · ₩4.7T₩369,500+5.42%
- SAM Chun Dang Pharm000250 · ₩4.5T₩190,000+1.28%
Recent filings
See all- Amended: Change of largest shareholderOct 28, 2026
- Amended: Shareholders' meeting calledOct 27, 2026
- [Amended] Small-Scale Public Offering Disclosure Documents (Equity Securities)Oct 27, 2026
- [Amended] Reference Document for Proxy Solicitation of Voting RightsOct 27, 2026
- Amended: Notice of shareholders' meetingOct 27, 2026
Titles in Korean until English translations are added.
Also known as: MOA Life Plus / 모아라이프플러스 / 142760 / KRX:142760
Source: KRX statistical information